Slide 1: Letter to stock exchanges: Investor / Analysts Presentation
February 10, 2024 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI -400 051 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Compan
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q3FY24
Aurobindo Pharma Limited Earnings Presentation Q3FY24
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q3FY24 Business & Financial Highlights 10 Update on biosimilars 12 Financial Summary 13 15 Filings Snapshot 3
Slide 5: Q3FY24 Business & Financial Highlights
Q3FY24 Business & Financial Highlights 4
Slide 6: Quarterly Performance – Q3 FY24
Quarterly Performance – Q3 FY24 Revenue (Rs Crore) US Revenue excluding Puerto Rico (US$ Mn) 7,219 7,352 6,851 451 6,407 6,473 382 409 5,739 355 359 313 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 EBITDA (Rs Crore) Net Debt to Equity 1,601 1,403 -0.01 1,151 95
Slide 7: Consolidated Financial & Business Highlights – Q3 FY24
Consolidated Financial & Business Highlights – Q3 FY24 Revenue from operations at Rs 7,352 Crore, an increase of 14.7% YoY | US revenues (excl. Puerto Rico) at US$ 451 Mn EBITDA before Forex and Other income at Rs 1,601 Crore | EBITDA margin is at 21.8% Net Profit after minority interest is at Rs 93
Slide 8: Consolidated Operational Performance
Consolidated Operational Performance Rs Crore Q3FY24 Q3FY23 Y-o-Y (%) Q2FY24 Q-o-Q (%) USA** 3,756 2,915 28.9% 3,385 11.0% Europe 1,728 1,701 1.6% 1,769 -2.3% Growth Markets* 627 499 25.6% 564 11.2% ARV 179 251 -28.6% 250 -28.2% Total Formulations 6,291 5,366 17.2% 5,968 5.4% Betalactum 737 623 18.3
Slide 9: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 500 451 409 400 355 300 • US revenue in Q3FY24 increased by 27.1% YoY and 10.2% QoQ 200 to USD 451 Mn, accounting for 51.1% of consolidated revenue 100 • Specialty & Injectables revenue in the US was
Slide 10: Europe, Growth Markets, ARV, API Business Revenues & Performance Highlights
Europe, Growth Markets, ARV, API Business Revenues & Performance Highlights Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (Rs Crore) 75 1,166 203 68 197 193 61 1,022 955 31 30 22 Q3FY23 Q2FY24 Q3FY24 Q3FY23 Q2FY24 Q3FY24 Q3FY23 Q2FY24 Q3FY24 Q3FY23 Q2FY24 Q3FY24 Growth Markets posted reve
Slide 11: Update on Biosimilars
Update on Biosimilars 10
Slide 12: Advancing our Oncology and Immunology Biosimilar Programs - Biologics
Advancing our Oncology and Immunology Biosimilar Programs -Biologics • CuraTeQ Biologics is a wholly owned subsidiary of Aurobindo Pharma Ltd • Our business strategy primarily focuses on developing Oncology and Immunology biosimilars • Our broader pipeline of 14 biosimilars positions CuraTeQ uniquel
Slide 13: Financial Summary
Financial Summary 12
Slide 14: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q3FY24 Q3FY23 YoY Chg. (%) Q2FY24 QoQ Chg. (%) Revenue from operations 7,352 6,407 14.7% 7,219 1.8% Gross Profit 4,201 3,500 20.0% 3,983 5.5% Gross Margin 57.1% 54.6% 253 bps 55.2% 198 bps Overheads -2,600 -2,545 2.2% -2,579 0.8% EBITDA (befor
Slide 15: Debt profile
Debt profile Gross debt (US$ Mn) Debt as on (INR Cr) Mar-20 Mar-21 Mar-22 Mar-23 Dec-23 Closing Rate (INR/USD) 75.665 73.110 75.793 82.170 83.212 732 674 313 592 752 815 Fx Loan restated in INR 5,549 4,929 2,223 4,638 4,907 Rupee Loan 17 44 150 224 1,873 Gross Debt 5,566 4,972 2,373 4,862 6,780 180
Slide 16: Filing Snapshot
Filing Snapshot 15
Slide 17: US ANDA Filings Snapshot as on 31st December 2023
US ANDA Filings Snapshot as on 31st December 2023 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ 641 CNS 145 24.8 Aurobindo (Excl. Specialty & 700 600 164 Specialty & Injectables 180 477 600 160 ARV** 28 0.5 500 500 140 120 Injectables) 400 400 100 42.2 300 CVS 110 300 52 80 148 200 20
Slide 18: Global regulatory filing Details
Global regulatory filing Details As at As at As at As at As at As at As at As at As at As at As at Category Geography Approvals Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Jun 23 Sep 23 Dec 23 US* 398 429 478 541 586 639 727^ 774^ 814^ 817^ 820 FA: 641, TA:31 3,219 Dossiers (422 Europe**
Slide 19: Thank You
Thank You Digitally signed by BADDIGAM ADI REDDY Date: 2024.02.10 18:08:59 +05'30' For more information, contact: ir@aurobindo.com; ccommunications@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1551 | 6672 5005 18